Biogen (BIIB) reported second quarter 2026 total revenue of $2.7 billion, up 3% year over year. GAAP diluted EPS was $0.66, while GAAP net income attributable to Biogen was $97.5 million.
The company said its Growth Portfolio generated $1.06 billion of revenue, up 24% year over year, and exceeded revenue from its legacy multiple sclerosis portfolio. Biogen also updated full year 2026 guidance, with total revenue expected to increase by a mid-single digit percentage compared with 2025.
- Second quarter total revenue was $2.736 billion, compared with $2.646 billion a year earlier.
- GAAP net income attributable to Biogen was $97.5 million, compared with $634.8 million in the prior-year quarter.
- GAAP basic EPS and GAAP diluted EPS were both $0.66.
- SPINRAZA revenue was $402 million, SKYCLARYS revenue was $168 million, and ZURZUVAE revenue was $71 million.
- Biogen completed the Apellis acquisition, with $97 million of SYFOVRE revenue and $30 million of EMPAVELI revenue recognized after the May 14 close.
- Full year 2026 reported non-GAAP diluted EPS guidance was updated to $12.00 to $13.00.
$BIIB Insider Trading Activity
$BIIB insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 3,408 shares for an estimated $665,664.
- NICOLE MURPHY (Head of Pharm Ops and Tech) purchased 3 shares for an estimated $585
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BIIB Hedge Fund Activity
We have seen 466 institutional investors add shares of $BIIB stock to their portfolio, and 384 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,381,678 shares (+35.9%) to their portfolio in Q1 2026, for an estimated $619,963,027
- POINT72 ASSET MANAGEMENT, L.P. removed 2,003,575 shares (-71.2%) from their portfolio in Q1 2026, for an estimated $367,315,404
- BLACKROCK, INC. added 1,163,231 shares (+7.9%) to their portfolio in Q1 2026, for an estimated $213,255,139
- MILLENNIUM MANAGEMENT LLC removed 1,031,622 shares (-91.7%) from their portfolio in Q1 2026, for an estimated $189,127,261
- BARCLAYS PLC removed 753,533 shares (-57.7%) from their portfolio in Q1 2026, for an estimated $138,145,204
- WELLINGTON MANAGEMENT GROUP LLP removed 589,628 shares (-16.6%) from their portfolio in Q1 2026, for an estimated $108,096,501
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 521,385 shares (-78.8%) from their portfolio in Q1 2026, for an estimated $95,585,512
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BIIB Congressional Stock Trading
Members of Congress have traded $BIIB stock 7 times in the past 6 months. Of those trades, 6 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/05, 01/30 and 0 sales.
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 4 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 1 sale worth up to $50,000 on 06/02.
- SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
